好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pharmacological treatment of status epilepticus at UNMC: assessment of seizure outcomes
Epilepsy/Clinical Neurophysiology (EEG)
P2 - Poster Session 2 (5:30 PM-6:30 PM)
6-025

To assess the effectiveness of treatment for status epilepticus (SE) and determine patient outcomes related to the delayed control of seizures at an urban tertiary care hospital. 

SE is a neurological emergency known to be related to high morbidity and mortality and requires prompt termination. It is important to evaluate the effectiveness of the current treatment for SE to improve patient care.  

Retrospective chart review was performed on 1565 adult patients who underwent continuous video electroencephalography (cvEEG) for suspected seizures at the University of Nebraksa Medical Center (UNMC) between January 1, 2012 and February 28, 2018. 

49 patients had and were treated for 64 incidences of convulsive or nonconvulsive SE recorded on cvEEG or clinical seizures longer than 5 min which were documented by a neurologist. Among 64 cases, 55 incidences required the second antiepileptic drug (AED), and 40 out of 55 cases were treated with the third AED subsequently. The mean seizure detection-to-needle time for the first, second, and third AEDs were 167, 239, and 297 minutes, respectively. Benzodiazepines were administered as the first AED in only 46 % of all treated cases. The duration of the hospital stays in patients treated with the first AED within 60 min after seizure detection was shorter compared to those whose treatment was delayed (23.0 vs. 33.6 days, p=0.41). The mortality rate in the former group was lower than that in the group which did not receive AEDs within 60 min (28.6 vs. 53.6%, p=0.02). 

The current treatment for SE at UNMC is inefficient with significant delay in delivery of medications after seizure detection; it may contribute to the prolonged hospital stay and increased mortality. In order to improve patient care, a protocol for the efficient treatment of SE must be established. 

Authors/Disclosures
Hae Young Baang, MD (Mount Sinai Health System)
PRESENTER
Dr. Baang has nothing to disclose.
Nicholas Swingle, MD (Cleveland Clinic) No disclosure on file
Kalyan C. Sajja, MD (Eagle Telemedicine) No disclosure on file
Deepak Madhavan, MD (Boys Town National Research Hospital) No disclosure on file
Olha Taraschenko, MD, PhD (University of Nebraska Medical Center) The institution of Dr. Taraschenko has received research support from NIH. The institution of Dr. Taraschenko has received research support from DHSS LB606 Nebraska Stem Cell Grant . Dr. Taraschenko has received personal compensation in the range of $0-$499 for serving as a Speaker with AES.